Works matching DE "BLOOD coagulation factor VIII antibodies"
Results: 791
Association of bullous pemphigoid with acquired hemophilia A: a case report.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Acute renal failure as a complication of acquired hemophilia due to autoantibody to factor VIII.
- Published in:
- Clinical & Experimental Nephrology, 2010, v. 14, n. 1, p. 85, doi. 10.1007/s10157-009-0226-y
- By:
- Publication type:
- Article
Dr. Rita Sarkar: SFG distinguished service award acceptance speech.
- Published in:
- Glycobiology, 2024, v. 34, n. 1, p. 1, doi. 10.1093/glycob/cwad102
- By:
- Publication type:
- Article
Prevalence of Hemophilia and Clinicodemographic Characteristics of Hemophilic Patients Aged ≤ 18 Years in Thi-Qar, Iraq.
- Published in:
- Global Pediatric Health, 2024, p. 1, doi. 10.1177/2333794X241280119
- By:
- Publication type:
- Article
Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2010, v. 102, n. 13, p. 942, doi. 10.1093/jnci/djq211
- By:
- Publication type:
- Article
CTLA-4 +49A/G And -318 C/T Polymorphisms and Cytokines Level on Inhibitors Development of Haemophilia A among Different Ethnicity in Malaysia.
- Published in:
- Malaysian Journal of Medicine & Health Sciences, 2022, v. 18, p. 2, doi. 10.47836/mjmhs18.s21.2
- By:
- Publication type:
- Article
A peculiar Factor VIII-related antigen staining of an oxyphilic cell nodule within an intrathyroidal parathyroid adenoma.
- Published in:
- Pathology International, 1999, v. 49, n. 3, p. 266, doi. 10.1046/j.1440-1827.1999.00860.x
- By:
- Publication type:
- Article
Allergic contact dermatitis to regenerated oxidized cellulose contained in a matrix employed for wound therapy.
- Published in:
- Contact Dermatitis (01051873), 2007, v. 57, n. 1, p. 47, doi. 10.1111/j.1600-0536.2007.01061.x
- By:
- Publication type:
- Article
Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 2, p. 176, doi. 10.3390/biom12020176
- By:
- Publication type:
- Article
The Role of Protein Tyrosine Phosphatase (PTP)-1B in Cardiovascular Disease and Its Interplay with Insulin Resistance.
- Published in:
- Biomolecules (2218-273X), 2019, v. 9, n. 7, p. 286, doi. 10.3390/biom9070286
- By:
- Publication type:
- Article
Acquired Hemophilia A with Gastrointestinal Bleeding.
- Published in:
- Clinical Endoscopy, 2020, v. 53, n. 1, p. 90, doi. 10.5946/ce.2019.036
- By:
- Publication type:
- Article
NXT007 does not interfere with the anticoagulant effects on tissue factor pathway inhibitor.
- Published in:
- Haemophilia, 2024, v. 30, n. 6, p. 1435, doi. 10.1111/hae.15106
- By:
- Publication type:
- Article
Evaluating the benefits of emicizumab prophylaxis for haemophilia A with inhibitors: A cost‐effectiveness and budget impact analysis in Thailand's upper‐middle income setting.
- Published in:
- Haemophilia, 2024, v. 30, n. 6, p. 1288, doi. 10.1111/hae.15105
- By:
- Publication type:
- Article
Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A.
- Published in:
- Haemophilia, 2024, v. 30, n. 5, p. 1138, doi. 10.1111/hae.15071
- By:
- Publication type:
- Article
Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience.
- Published in:
- Haemophilia, 2024, v. 30, n. 5, p. 1247, doi. 10.1111/hae.15086
- By:
- Publication type:
- Article
Minimal interference of concizumab with standard clinical coagulation laboratory assays – An in vitro study.
- Published in:
- Haemophilia, 2024, v. 30, n. 4, p. 1059, doi. 10.1111/hae.15070
- By:
- Publication type:
- Article
Comparison of the kinematic analysis of indoor and outdoor gait in people with haemophilia and total knee replacement.
- Published in:
- Haemophilia, 2024, v. 30, n. 4, p. 1102, doi. 10.1111/hae.15061
- By:
- Publication type:
- Article
Prophylaxis with emicizumab in children under 12 years old with haemophilia A without inhibitors in Uruguay: National experience.
- Published in:
- Haemophilia, 2024, v. 30, n. 4, p. 1077, doi. 10.1111/hae.15024
- By:
- Publication type:
- Article
Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor.
- Published in:
- Haemophilia, 2024, v. 30, n. 3, p. 868, doi. 10.1111/hae.15022
- By:
- Publication type:
- Article
Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry.
- Published in:
- Haemophilia, 2024, v. 30, n. 3, p. 685, doi. 10.1111/hae.15015
- By:
- Publication type:
- Article
Primary prophylaxis implementation and long‐term joint outcomes in Swedish haemophilia A patients.
- Published in:
- Haemophilia, 2024, v. 30, n. 3, p. 671, doi. 10.1111/hae.15013
- By:
- Publication type:
- Article
Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries.
- Published in:
- Haemophilia, 2024, v. 30, n. 3, p. 575, doi. 10.1111/hae.14968
- By:
- Publication type:
- Article
Genetic predictors for FVIII inhibitors formation in a Greek population of children with severe haemophilia A exclusively treated with recombinant concentrates.
- Published in:
- Haemophilia, 2024, v. 30, n. 3, p. 845, doi. 10.1111/hae.14957
- By:
- Publication type:
- Article
Long‐term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post‐treatment.
- Published in:
- Haemophilia, 2024, v. 30, n. 2, p. 320, doi. 10.1111/hae.14936
- By:
- Publication type:
- Article
Emicizumab and asparaginase, A first experience to share.
- Published in:
- Haemophilia, 2024, v. 30, n. 2, p. 561, doi. 10.1111/hae.14935
- By:
- Publication type:
- Article
Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post‐marketing study.
- Published in:
- Haemophilia, 2024, v. 30, n. 2, p. 388, doi. 10.1111/hae.14930
- By:
- Publication type:
- Article
Cost‐effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India.
- Published in:
- Haemophilia, 2024, v. 30, n. 2, p. 426, doi. 10.1111/hae.14921
- By:
- Publication type:
- Article
The effects of time and temperature on the in vitro stability of emicizumab in blood samples: Implications for laboratory and clinical practices.
- Published in:
- Haemophilia, 2024, v. 30, n. 2, p. 554, doi. 10.1111/hae.14923
- By:
- Publication type:
- Article
Main Congress Oral Abstracts.
- Published in:
- Haemophilia, 2024, v. 30, p. 18, doi. 10.1111/hae.14916
- Publication type:
- Article
Hybrid human‐porcine factor VIII proteins partially escape the inhibitory effects of anti‐factor VIII inhibitor alloantibodies having A2 or C2 domain specificity.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 140, doi. 10.1111/hae.14911
- By:
- Publication type:
- Article
Safety, pharmacokinetics and efficacy of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 123, doi. 10.1111/hae.14898
- By:
- Publication type:
- Article
Blue toe syndrome, severe haemophilia A and emicizumab.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 241, doi. 10.1111/hae.14893
- By:
- Publication type:
- Article
Two‐center validation of assays for the detection of binding and neutralizing anti‐factor VIII antibodies.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 224, doi. 10.1111/hae.14885
- By:
- Publication type:
- Article
Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan.
- Published in:
- Haemophilia, 2023, v. 29, n. 6, p. 1499, doi. 10.1111/hae.14880
- By:
- Publication type:
- Article
Cases of less‐than‐expected FVIII activity in previously treated patients during post‐marketing surveillance of N8‐GP.
- Published in:
- Haemophilia, 2023, v. 29, n. 6, p. 1475, doi. 10.1111/hae.14864
- By:
- Publication type:
- Article
Development of VIII inhibitors beyond 50 exposure days to rFVIII during prophylactic emicizumab therapy.
- Published in:
- Haemophilia, 2023, v. 29, n. 6, p. 1653, doi. 10.1111/hae.14854
- By:
- Publication type:
- Article
Acquired haemophilia A: A 15‐year population‐based review of incidence rate, patient demographics and treatment outcomes.
- Published in:
- Haemophilia, 2023, v. 29, n. 5, p. 1269, doi. 10.1111/hae.14845
- By:
- Publication type:
- Article
Development of inhibitors in women with mild haemophilia A and concurrent treatment with immune tolerance therapy and emicizumab.
- Published in:
- Haemophilia, 2023, v. 29, n. 4, p. 1167, doi. 10.1111/hae.14821
- By:
- Publication type:
- Article
Real‐world data for the use of emicizumab in haemophilia A patients with inhibitors – First nationwide report from Korea.
- Published in:
- Haemophilia, 2023, v. 29, n. 4, p. 1163, doi. 10.1111/hae.14819
- By:
- Publication type:
- Article
Bleeding events in people with congenital haemophilia A without factor VIII inhibitors receiving prophylactic factor VIII treatment: A systematic literature review.
- Published in:
- Haemophilia, 2023, v. 29, n. 4, p. 954, doi. 10.1111/hae.14803
- By:
- Publication type:
- Article
Emicizumab for acquired haemophilia A: A case series.
- Published in:
- Haemophilia, 2023, v. 29, n. 4, p. 1049, doi. 10.1111/hae.14809
- By:
- Publication type:
- Article
No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients.
- Published in:
- Haemophilia, 2023, v. 29, n. 4, p. 1039, doi. 10.1111/hae.14808
- By:
- Publication type:
- Article
Long‐term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients.
- Published in:
- Haemophilia, 2023, v. 29, n. 4, p. 1005, doi. 10.1111/hae.14796
- By:
- Publication type:
- Article
Deciphering a novel complex inversion affecting F8 in a family with severe haemophilia A by optical genome mapping.
- Published in:
- Haemophilia, 2023, v. 29, n. 3, p. 921, doi. 10.1111/hae.14771
- By:
- Publication type:
- Article
POSTER ABSTRACTS.
- Published in:
- Haemophilia, 2023, v. 29, p. 24, doi. 10.1111/hae.14715
- By:
- Publication type:
- Article
Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors.
- Published in:
- Haemophilia, 2023, v. 29, n. 1, p. 348, doi. 10.1111/hae.14685
- By:
- Publication type:
- Article
Effectiveness of monthly low dose emicizumab prophylaxis without 4‐week loading doses among patients with haemophilia A with and without inhibitors: A case series report.
- Published in:
- Haemophilia, 2023, v. 29, n. 1, p. 382, doi. 10.1111/hae.14707
- By:
- Publication type:
- Article
Emicizumab assays evaluations with four different reagents in severe haemophilia A patients: Concentration from baseline to maintenance therapy.
- Published in:
- Haemophilia, 2023, v. 29, n. 1, p. 374, doi. 10.1111/hae.14703
- By:
- Publication type:
- Article
Life‐threatening complication of central venous catheter in a child with severe haemophilia A.
- Published in:
- Haemophilia, 2023, v. 29, n. 1, p. 367, doi. 10.1111/hae.14697
- By:
- Publication type:
- Article
First case report on persistent patellar dislocation in haemophilia A patient with a factor VIII inhibitor.
- Published in:
- Haemophilia, 2022, v. 28, n. 5, p. e113, doi. 10.1111/hae.14606
- By:
- Publication type:
- Article